November 10, 2026 · Phase 2 readout
TLSA Phase 2 readout: a negative outcome, -9.0%
On November 10, 2026, Foralumab Nasal — Tiziana Life Sciences Ltd (Multiple System Atrophy) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -9.0% in the window around the event. It had already run -42.0% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$0.67
1d before
$0.61
Event day
$0.62
1d after
$0.57
5d after
Pre-catalyst setup
-42.0%
30-day run-up
9510%
30-day volatility
0.5×
volume spike
